Symbols

NVCR

Novocure·NASDAQ

--(--)

NVCR fundamentals

NVCR Q4 2025 Earnings

Novocure (NVCR) released its earnings on Feb 26, 2026: revenue was 174.35M (YoY +8.11%), missed estimates; EPS was -0.22 (YoY +63.93%), beat estimates.

Revenue / YoY

174.35M

+8.11%

EPS / YoY

-0.22

+63.93%

Report date

Feb 26, 2026

NVCR Earnings Call Summary for Q4,2025

FDA Approval Milestone: Optune Pax for pancreatic cancer approved 3 months ahead of schedule.
2026 Growth Path: $675-705M revenue target (+3-8%), driven by GBM ex-US expansion and new indications.
Profitability Focus: 2026 adj. EBITDA guidance of -20M to breakeven reflects cost discipline.
Key Risk: 1-2 year payer coverage timeline for Optune Pax may delay revenue realization.

Earnings

EPS

Revenue

Revenue & Expenses

NVCR has released its 2025 Q4 earnings report, with revenue of 174.35M, reflecting a YoY change of 8.11%, and net profit of -24.50M, showing a YoY change of 62.84%. The Sankey diagram below clearly presents NVCR's revenue sources and cost distribution.

Key Indicators

Novocure (NVCR) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Novocure (NVCR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Novocure (NVCR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Novocure (NVCR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown